Edition:
India

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

1.95USD
20 Apr 2018
Change (% chg)

$-0.05 (-2.50%)
Prev Close
$2.00
Open
$1.98
Day's High
$2.01
Day's Low
$1.91
Volume
6,785
Avg. Vol
37,649
52-wk High
$21.86
52-wk Low
$1.71

Chart for

About

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal... (more)

Overall

Beta: -8.40
Market Cap(Mil.): $71.13
Shares Outstanding(Mil.): 0.12
Dividend: --
Yield (%): --

Financials

BRIEF-Akari Therapeutics Qtrly Loss Per Common Share $0.01

* AKARI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS

21 Mar 2018

BRIEF-Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful

* AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT

09 Dec 2017

Earnings vs. Estimates